Pharmacoeconomic Communications To Payers Getting Multiple Pilots By Genentech
Bristol, Genentech execs describe how their companies are adapting to US FDA loosening some restrictions on how sponsors can talk about data that are 'related to' approved indications.
You may also be interested in...
US FDA should apply same regulatory protections to manufacturer communications with payers about unapproved uses that agency draft guidance provides to information exchanges about investigational products, biopharma companies say.
US Academy of Managed Care Pharmacy is developing language to protect exchange of clinical and economic information on pipeline products between manufacturers and healthcare decision-makers; safe harbor could find a home in legislation reauthorizing FDA user fee programs.
Germany uses government facilitated price negotiations between publicly funded insurers and manufacturers that are based on an independent assessment of how much added value a drug provides.